238 related articles for article (PubMed ID: 37525116)
21. [Diagnostic value of serum alpha-fetoprotein, alpha-fetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma].
Hu RZ; Zhao SQ; Shen B; Guo GB
Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):634-637. PubMed ID: 31594082
[No Abstract] [Full Text] [Related]
22. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
[TBL] [Abstract][Full Text] [Related]
23. Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma.
Huang F; Yang G; Jiang H; Chen X; Yang Y; Yu Q; Pan B; Wang B; Guo W; Yang W; Zhang C
Technol Cancer Res Treat; 2022; 21():15330338221144510. PubMed ID: 36573042
[No Abstract] [Full Text] [Related]
24. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
[TBL] [Abstract][Full Text] [Related]
25. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
[TBL] [Abstract][Full Text] [Related]
26. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study.
Wang MD; Sun LY; Qian GJ; Li C; Gu LH; Yao LQ; Diao YK; Pawlik TM; Lau WY; Huang DS; Shen F; Yang T
Int J Surg; 2022 Sep; 105():106843. PubMed ID: 35995351
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma.
Tian S; Chen Y; Zhang Y; Xu X
J Clin Lab Anal; 2023 Jan; 37(1):e24823. PubMed ID: 36579611
[TBL] [Abstract][Full Text] [Related]
28. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic accuracy of serum protein induced by vitamin K absence (PIVKA-II), serum a-fetoprotein and their combination for hepatocellular carcinoma among Caucasian cirrhotic patients with diagnostic or non-diagnostic serum a-fetoprotein levels.
Syriha A; Pantzios S; Mandilara D; Galanis P; Stathopoulou I; Barla G; Elefsiniotis I
Cancer Med; 2024 Feb; 13(3):e6825. PubMed ID: 38361401
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of protein induced by absence of vitamin K absence or antagonist II, alpha-fetoprotein and gamma-glutamyltransferase/aspartate aminotransferase ratio for the diagnosis of hepatocellular carcinoma in transplantation candidates.
Ekmen N; Akalin Ç; Akyildiz M
Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):294-299. PubMed ID: 32796360
[TBL] [Abstract][Full Text] [Related]
31. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
32. [The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma].
Zhang JW; Guan LY; E CY; Yang JH; Xuan W; Meng ZH; Li W
Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):776-781. PubMed ID: 32993265
[No Abstract] [Full Text] [Related]
33. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.
Malik J; Klammer M; Rolny V; Chan HL; Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; Swiatek-de Lange M
World J Gastroenterol; 2022 Aug; 28(29):3917-3933. PubMed ID: 36157551
[TBL] [Abstract][Full Text] [Related]
34. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
[TBL] [Abstract][Full Text] [Related]
35. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma.
Tran VT; Phan TT; Nguyen TB; Le TT; Tran TT; Nguyen AT; Nguyen HT; Nguyen NB; Ho TT; Pho SP; Nguyen TT; Nguyen HT; Mai HT; Pham BT; Nguyen KD; Le BT; Nguyen TT; Nguyen ST
BMC Res Notes; 2023 Nov; 16(1):317. PubMed ID: 37932802
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of AFP, PIVKA-II, and Their Combination in Diagnosing Hepatocellular Carcinoma Based on Upconversion Luminescence Immunochromatography.
Zhang SG; Huang Y
Lab Med; 2022 Sep; 53(5):488-494. PubMed ID: 35551399
[TBL] [Abstract][Full Text] [Related]
38. Integrated Predictors by Propensity Scoring With Tumor Markers and Plasma Levels of microRNA-21-5p, IL-17, and IL-10 Complement Early Detection of Hepatocellular Carcinoma in Patients With Liver Cirrhosis.
Machida M; Ambo M; Mishina R; Hada N; Tachibana F; Yamashita M; Konda A; Tsuji K
Technol Cancer Res Treat; 2023; 22():15330338231212084. PubMed ID: 37960842
[No Abstract] [Full Text] [Related]
39. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma.
Qi F; Zhou A; Yan L; Yuan X; Wang D; Chang R; Zhang Y; Shi F; Han X; Hou J; Wei L; Zhang X
J Clin Lab Anal; 2020 May; 34(5):e23158. PubMed ID: 31821607
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal surveillance of three biomarkers to predict recurrence of hepatocellular carcinoma after radical resection.
Tong JS; Lu CD; Lu CJ; Zheng S; Mao SQ
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1178-1185. PubMed ID: 37577836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]